The headline is well known and it is correct. In February 2024 RAND published a comparison of US prescription prices against 33 other OECD countries, using 2022 manufacturer-level data. Across all drugs, Americans pay $2.78 for every dollar paid elsewhere.
The part almost nobody repeats is the part that matters most to anyone paying cash.
Two markets wearing one name
The United States does not have expensive drugs. It has an expensive brand market and an unusually cheap generic one, and quoting the blended average hides both.
RAND put US brand prices at 422% of the comparison countries. Adjusting for the rebates manufacturers pay behind the scenes — which nobody outside the contracts can measure precisely — brings the estimate down to at least 322%. Still three times.
Unbranded generics came in at roughly 67%. Cheaper than Canada, cheaper than most of Europe. And generics are not a niche: they are about 90% of prescription volume in the United States. Nine out of ten prescriptions filled here are drawn from the part of the system that works.
RAND is explicit that the cheap generics do not rescue the average. The brand prices are high enough, on drugs expensive enough, that the blend still lands at 2.78.
Why the two halves behave so differently
A generic has no exclusivity. The moment a patent expires, anyone with a manufacturing licence can make the molecule, and the price falls to something near the cost of production plus a thin margin. The US generic market is large, competitive and fast — which is exactly why it produces some of the lowest generic prices in the developed world.
A brand-name drug under patent has one seller. Every other wealthy country meets that single seller with a single buyer: a national body that negotiates one price, or refuses to list the drug. The US does not. It meets one seller with thousands of fragmented buyers, and until January 2026 the largest of them — Medicare — was prohibited by statute from negotiating at all.
Higher US brand prices are not purely extraction, and it is dishonest to present them that way. The US funds a disproportionate share of global pharmaceutical revenue, and that revenue underwrites development that other countries benefit from without paying for. Reasonable people disagree about how much of the premium is research and how much is market power, and the honest answer is that nobody outside the companies can decompose it precisely.
Two things are still true regardless of where you land on that. The rebate system makes the real price unknowable to the person paying it, and none of that argument applies to generics — which is where most people, and almost everything on this site, actually live.
What this means if you are paying cash
It tells you where effort is worth spending.
If your drug has a generic, you are in the functioning half of the market. The molecule is cheap, several manufacturers make it, and the difference between what one pharmacy charges and another is mostly overhead and margin rather than the drug. That gap is large and it is yours to close, which is what this site is for.
If your drug is brand-only, you are in the half where a cash payer has the least leverage in the world's highest-priced market. Shopping helps less. Manufacturer assistance programmes, which supply the drug free or heavily discounted below an income threshold, help far more — and are the single most under-used route we know of. There is a screener at the bottom of every page here.
It is also why the first question worth asking a prescriber is whether a generic exists at all, and the second is whether an older drug in the same class would do. Moving from the brand half to the generic half is worth more than any amount of comparison shopping within the brand half.
How to check your own drug
Search it by name or by condition. Every drug page shows what pharmacies paid to acquire it — the federal NADAC benchmark — against every cash price we can find. If the gap is small, the price you were quoted is ordinary. If it is several times over, the difference is not the drug.